Preoperative Hemogram Parameters and BRAF Molecular Test Detected by Bethesda 3 Cytology.
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorSaglik Bilimleri Universitesi
About this trial
The main hypothesis of this study is that preoperative hemogram parameters can be used as biomarkers for malignancy in patients with thyroid nodule Bethesda 3 cytology.
The secondary hypothesis is that BRAF molecular testing has a high predictive value in predicting malignancy in patients with thyroid nodule Bethesda 3 cytology.
Primary outcome: Preoperative hemogram parameters. Secondary outcome: BRAF positivity.
Eligibility criteria
Qualifiers
Patients between the ages of 18 -75
Patients who were diagnosed with Bethesda III as a result of preoperative FNAC and decided to undergo thyroidectomy
Disqualifiers
Patients over 18 years old and under 75 years old
Patients with malignancy detected in another focus with preoperative Bethesda III FNAC
Detection of malignancy in another focus other than the nodule with Bethesda III cytological result after thyroidectomy
Failure to obtain preoperative hemogram results Patients who do not agree to participate in scientific studies for BRAF testing
Trial design
Treatments tested in this trial
- Not listed
Trial groups
120 Participants
are grouped into 1 trial groupSponsors and collaborators
Source ClinicalTrials.gov